Literature DB >> 21965080

Craniofacial morphology in patients with hypophosphatemic rickets: a cephalometric study focusing on differences between bone of cartilaginous and intramembranous origin.

Hans Gjørup1, Inger Kjaer, Liselotte Sonnesen, Dorte Haubek, Signe Sparre Beck-Nielsen, Hanne Hintze, Sven Poulsen.   

Abstract

Hypophosphatemic rickets (HR) are diseases characterized by deficient mineralization of bone due to abnormal renal wasting of phosphate. Deformation of bony structures of cartilaginous origin has been described as a major characteristic in patients with HR, but little is known about the impact on bony structures of intramembranous origin. The aim of the present study was to describe the osseous morphology of the craniofacial structures in patients with HR compared to healthy controls, and to investigate the impact of different bone origin on the osseous morphology. Fifty-three patients with HR (17 males, 36 females), aged 3-74 yrs, were included. Fifty HR patients had dominant X-linked disease, and in three patients no mutations were identified. A total of 79 healthy individuals (37 males, 42 females), aged 6-79 yrs, with normal occlusion served as controls. Significant cephalometric differences were found between HR patients and controls. In HR patients, the cranial base was flattened and the depth of the posterior cranial fossa was decreased. The anterior height of the cranium, the angle nasion-sella-frontale, and the thickness of theca were increased. The length of the nasal bone and the height of the maxilla were reduced. In contrast, the vertical as well as the sagittal relation between the jaws were unaffected in HR patients compared to controls. In conclusion, we found that the cranial structures of cartilaginous origin as well as the structures of intramembraneous origin were affected in patients with HR.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21965080     DOI: 10.1002/ajmg.a.34242

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  7 in total

1.  Craniofacial and dental characteristics of patients with vitamin-D-dependent rickets type 1A compared to controls and patients with X-linked hypophosphatemia.

Authors:  Hans Gjørup; Signe Sparre Beck-Nielsen; Dorte Haubek
Journal:  Clin Oral Investig       Date:  2017-06-12       Impact factor: 3.573

2.  Tissue-nonspecific alkaline phosphatase deficiency causes abnormal craniofacial bone development in the Alpl(-/-) mouse model of infantile hypophosphatasia.

Authors:  Jin Liu; Hwa Kyung Nam; Cassie Campbell; Kellen Cristina da Silva Gasque; José Luis Millán; Nan E Hatch
Journal:  Bone       Date:  2014-07-09       Impact factor: 4.398

3.  Chiari I Malformation in Nephropathic Cystinosis.

Authors:  Kavya I Rao; John Hesselink; Doris A Trauner
Journal:  J Pediatr       Date:  2015-08-08       Impact factor: 4.406

Review 4.  Rare bone diseases and their dental, oral, and craniofacial manifestations.

Authors:  B L Foster; M S Ramnitz; R I Gafni; A B Burke; A M Boyce; J S Lee; J T Wright; S O Akintoye; M J Somerman; M T Collins
Journal:  J Dent Res       Date:  2014-04-03       Impact factor: 6.116

Review 5.  Pharmacological management of X-linked hypophosphataemia.

Authors:  Erik A Imel; Kenneth E White
Journal:  Br J Clin Pharmacol       Date:  2018-10-29       Impact factor: 4.335

Review 6.  FGF23, Hypophosphatemia, and Emerging Treatments.

Authors:  Erik A Imel; Andrew Biggin; Aaron Schindeler; Craig F Munns
Journal:  JBMR Plus       Date:  2019-05-13

Review 7.  Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium.

Authors:  Michaël R Laurent; Jean De Schepper; Dominique Trouet; Nathalie Godefroid; Emese Boros; Claudine Heinrichs; Bert Bravenboer; Brigitte Velkeniers; Johan Lammens; Pol Harvengt; Etienne Cavalier; Jean-François Kaux; Jacques Lombet; Kathleen De Waele; Charlotte Verroken; Koenraad van Hoeck; Geert R Mortier; Elena Levtchenko; Johan Vande Walle
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-19       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.